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Donghoon Choi, MD; Yangsoo Jang, MD; Myeong-Ki Hong, MD, PhD
Background-—The effects of severe acute stent malapposition (ASM) after drug-eluting stent implantation on long-term clinical
outcomes are not clearly understood. We evaluated long-term clinical outcomes of severe ASM using optical coherence
tomography.
Methods and Results-—We pooled patient- and lesion-level data from 6 randomized studies. Five studies investigated follow-up
drug-eluting stent strut coverage and one investigated ASM. In this data set, a total of 436 patients with 444 lesions underwent
postintervention optical coherence tomography examination and these data were included in the analysis. Severe ASM was deﬁned
as lesions with ≥400 lm of maximum malapposed distance or ≥1 mm of maximum malapposed length. Composite events (cardiac
death, target lesion–related myocardial infarction, target lesion revascularization, and stent thrombosis) were compared between
patients with and without severe ASM. The postintervention optical coherence tomography ﬁndings indicated that 62 (14.2%)
patients had lesions with ≥400 lm of maximum malapposed distance and 186 (42.7%) patients had lesions with ≥1 mm of
maximum malapposed length. The 5-year clinical follow-up was completed in 371 (86.1%) of the eligible 431 patients. The
cumulative rate of composite events was similar among the patients in each group during 5-year follow-up: 3.3% in patients with
ASM ≥400 lm of maximum malapposed distance versus 3.1% in those with no ASM or ASM <400 lm of maximum malapposed
distance (P=0.89), and 1.2% in patients with ASM ≥1 mm of maximum malapposed length versus 4.6% in those with no ASM or
ASM <1 mm of maximum malapposed length (P=0.06).
Conclusions-—During the 5-year follow-up, ASM severity was not associated with long-term clinical outcomes in patients treated
with drug-eluting stents. ( J Am Heart Assoc. 2019;8:e012800. DOI: 10.1161/JAHA.119.012800.)
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A cute stent malapposition (ASM) is frequently observed inpercutaneous coronary intervention. However, the clin-
ical effects of ASM following drug-eluting stent (DES)
implantation remain controversial. Analyses of large multi-
center registries of patients who underwent postintervention
optical coherence tomography (OCT) assessment suggested
that neither the presence nor the severity of acute malappo-
sition were associated with clinical outcome.1,2 However,
recent analyses of several stent thrombosis registries
consistently found that extensively malapposed struts were
frequently identiﬁed in patients who experienced stent
thrombosis.3–5 Despite current uncertainties regarding the
clinical relevance and potential sequelae of ASM, an expert
consensus of the European Association of Percutaneous
Cardiovascular Interventions recommended avoidance of
extensive ASM (ie, maximum malapposed distance
≥400 lm or maximum malapposed length ≥1 mm), and
correction when anatomically feasible.6 This recommendation
was based on OCT studies that investigated associations
between ASM and subsequent integration by neointimal
tissue.7–9 However, the stent optimization criteria to minimize
ASM require further validation.
Based on the European Association of Percutaneous
Cardiovascular Interventions’ proposed postintervention opti-
mization targets for ASM,6 the aims of this study were: (1) to
evaluate the incidence of severe ASM after DES implantation,
(2) to observe serial changes in severe ASM using follow-up
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OCT examination, and (3) to compare 5-year clinical outcomes
between patients with and without severe ASM.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
We pooled patient- and lesion-level data from 6 randomized
studies that investigated follow-upDES strut coverage (5 studies)
and ASM (1 study).10–15 The study ﬂow diagram is presented in
Figure 1. The details of these studies are presented in Tables 1
and 2. The 6 studies had similar characteristics and inclusion/
exclusion criteria. These OCT studies included patients who
underwent a single or short-length DES implantation for
noncomplex lesions and excluded those with complex coronary
lesions (eg, diffuse long lesions requiring multiple or long stents,
unprotected left main stenosis, bifurcation, chronic total occlu-
sion, and severe calciﬁcation). All studies were performed by
Severance Cardiovascular Hospital researchers. The angio-
graphic and OCT data from these studies were analyzed at a
single core laboratory (Cardiovascular Research Center, Seoul,
Korea). Final OCT ﬁndings after the completion of study
procedures were used for postintervention OCT data. To be
consistentwith other studies,10,12–14 the data fromearlier follow-
ups were used when studies had >1 OCT follow-up.11,15 From a
total of 491 randomized patients, 436 patients with 444 DES-
treated lesions underwent postintervention OCT examination.
The data from these patients were included in the analysis. Each
patient received at least 75 mg of aspirin and a loading dose of
300 mg of clopidogrel at least 12 hours before intervention.
During the intervention, unfractionated heparin was adminis-
tered to maintain an activated clotting time of >250 seconds.
Stent implantation was performed according to current standard
techniques. If a patient had >1 lesion to treat, all were treated
using the assigned study procedures. Patients continued to take
100 mg of aspirin and 75 mg of clopidogrel daily for at least
12 months after stent implantation. The individual study proto-
cols were approved by the institutional review board of our
hospital. Written informed consent was obtained from each
enrolled patient.
Coronary Angiographic and OCT Analyses
Quantitative coronary angiography analysis was performed
using an ofﬂine computerized quantitative coronary angio-
graphic system (CAAS, Pie Medical Imaging). Using the guiding
catheter for magniﬁcation-calibration, minimal lumen diameter
and reference vessel diameter of the treated coronary lesions
were measured from diastolic frames in a single and matched
view showing the smallest minimal lumen diameters. The
reference vessel diameter was an average of proximal and
distal segment measurements of the reference vessel.
Two types of OCT systems (time-domain M2 or frequency-
domain C7-XR; LightLab Imaging, Inc., St. Jude Medical) were
used in the present study (Table 1). The detailed OCT imaging
methods were described in previous studies.10–16 The OCT
procedure and image acquisition were previously described.10–
15 All OCT images were analyzed using certiﬁed ofﬂine software
(QIvus, Medis Medical Imaging Systems) at a core laboratory
(Cardiovascular Research Center) by analysts who were blinded
to patient and procedural information.16 All cross-sectional
images were analyzed at 1-mm intervals. Because OCT ﬁndings
from 3 studies were measured at 0.2-mm intervals, these data
were reanalyzed at 1-mm intervals.11,12,15 The stent and lumen
cross-sectional areas were measured, and neointimal hyper-
plasia cross-sectional area was calculated as the stent minus
lumen cross-sectional area. Lumen, stent, and neointima
volumes were estimated using Simpson’s rule, and the
corresponding volume index was calculated as the volume
divided by measured longitudinal length. A malapposed strut
was deﬁned as a strut that was detached from the vessel wall
as follows: sirolimus-eluting stent (≥160 lm, Cypher, Cordis);
zotarolimus-eluting stent (≥110 lm, Endeavor Resolute, Med-
tronic CardioVascular); everolimus-eluting stent (≥100 lm,
Xience, Abbott Vascular and Promus Element, Boston Scien-
tiﬁc); and biolimus-eluting stent (≥130 lm Nobori, Terumo
Corp. and Biomatrix, Biosensors International).10–15 If the OCT
examination revealed a malapposed strut, maximum malap-
posed distance and consecutive length were determined per
stented lesion. Severe ASM was arbitrarily deﬁned as lesions
with ≥400 lm of maximum malapposed distance or ≥1 mm of
maximum malapposed length.6
Clinical Outcomes
The clinical data were obtained from medical record
reviews. All deaths were considered cardiac deaths unless
Clinical Perspective
What Is New?
• Severe acute stent malapposition was not associated with
adverse clinical events during the post–drug-eluting stent
implantation 5-year follow-up.
What Are the Clinical Implications?
• Additional interventional procedures for severe acute stent
malapposition may not be necessary.
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a deﬁnite noncardiac cause was established.17 Myocardial
infarction after discharge was deﬁned as the presence of
clinical symptoms, electrocardiographic changes, or abnor-
mal echocardiographic ﬁndings accompanied by an increase
in the creatine kinase myocardial band fraction above the
upper limit or an increase in troponin-T or troponin-I levels
to greater than the 99th percentile of the upper normal
limit. Deﬁnite or probable stent thrombosis was deﬁned
according to the recommendations of the Academic
Research Consortium.17 Target lesion revascularization
was deﬁned as any repeat percutaneous intervention of
the target lesion or bypass surgery of the target vessel
Figure 1. Study ﬂow diagram. OCT indicates optical coherence tomography.
Table 1. Main Characteristics of 6 Randomized OCT Studies
Study Patients (Lesions), No. Study Procedures OCT Systems and Examinations Primary Outcome Results
Kim et al10 40 (41) ZES-R vs EES M2; postprocedure, 3 mo Strut coverage Comparable
Kim et al11 60 (60) BES vs SES C7-XR; postprocedure, 3 and 12 mo Strut coverage BES better
Kim et al12 120 (120) BES vs SES C7-XR; postprocedure, 6 mo Strut coverage BES better
Kim et al13 100 (100) PtCr-EES vs CoCr-EES C7-XR; postprocedure, 3 mo Strut apposition PtCr-EES possibly better
Kim et al14 117 (124) OCT vs angiography guidance C7-XR; postprocedure, 6 mo Strut coverage OCT guidance better
Kim et al15 60 (64) EES vs SES C7-XR; postprocedure, 3 and 12 mo Strut coverage EES better
BES indicates biolimus-eluting stent; CoCr-EES, cobalt-chromium everolimus-eluting stent; EES, everolimus-eluting stent; OCT, optical coherence tomography; PtCr-EES, platinum-
chromium everolimus-eluting stent; SES, sirolimus-eluting stent; ZES-R, Resolute zotarolimus-eluting stent.
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performed for restenosis or other complications of the
target lesion.17
Statistical Analysis
Statistical analysis was performed using SAS (version 9.2;
SAS Institute). Continuous variables were reported as
meanSD or median (interquartile range) as appropriate
and were compared using Student t test or Wilcoxon rank sum
test. Categorical variables were reported as number
(percentage) and were compared using chi-square test or
Fisher exact test. OCT ﬁndings per lesion were reported as
median (interquartile range) and compared using a hierarchi-
cal multilevel regression model including patients and
individual studies as random effects. To evaluate independent
predictors for severe ASM, the odds ratio (OR) with 95% CI
was analyzed using a multivariable analysis. Clinically relevant
variables or variables with a P<0.10 on univariate analysis
were entered into a multivariable model: age, sex, current
smoking, clinical presentation of acute myocardial infarction,
Table 2. Inclusion and Exclusion Criteria of 6 Randomized OCT Studies
Kim et al10 Kim et al11 Kim et al12 Kim et al13 Kim et al14 Kim et al15
Major
inclusion
criteria
Stable or unstable
angina
De novo lesions with
significant stenosis
Vessel size of 2.5 to
3.5 mm by visual
estimation
that could be covered
by a single stent
Stable or unstable
angina and non–
ST-segment–
elevation MI
De novo lesions with
significant stenosis
Vessel size of 2.5 to
3.5 mm and stent
length ≤24 mm
Stable angina or
acute coronary
syndrome
De novo lesions with
significant stenosis
Vessel size of 2.5 to
3.5 mm and lesion
length ≤24 mm
Stable or unstable
angina
De novo lesions with
significant stenosis
Stent diameter of
2.5 to 3.5 mm and
stent length
≤24 mm
De novo lesions with
significant stenosis
Vessel size of 2.5 to
4.0 mm that could
be covered by a
single stent
Stable or unstable
angina and non–
ST-segment–
elevation MI
De novo lesions
with significant
stenosis
Vessel size of 2.5
to 3.5 mm and
stent length
≤24 mm
Major
exclusion
criteria
Unprotected left main
disease
Overlapping stents or
bifurcated lesions
Unsuitable lesions for
occlusion technique
ST-segment–
elevation MI
Complex lesion
morphologies
Diffuse long lesions
requiring multiple
or long (>28 mm)
stents
Complex lesion
morphologies
Acute MI
diffuse long
(≥28 mm) or
implantation of
multiple stents
Complex lesion
morphologies
Presence of an
overlapping stent
or long stent
(>30 mm)
Complex lesion
morphologies
ST-segment–
elevation MI
Complex lesion
morphologies
MI indicates myocardial infarction; OCT, optical coherence tomography.
Figure 2. Incidence of acute stent malapposition (ASM) after drug-eluting stent implantation.
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types of implanted stents, stent-to-reference vessel diameter
ratio, total stent length, and use of adjuvant balloon. Cumulative
incidence values for clinical events at 5 years were calculated
using the Kaplan–Meier estimate and were compared using a
Cox regression model that included individual studies as
random effects. Given the different patient enrollment among
the individual studies, events beyond 5 years were censored to
preserve analysis homogeneity. A P<0.05 was considered
statistically signiﬁcant for all analyses.
Results
ASM Distance
Lesions with ≥400 lm of maximal ASM distance were
identiﬁed in 63 of 444 (14.2%) lesions (Figure 2). The results
for baseline characteristics according to malapposed distance
are presented in Table 3. Angiography revealed that reference
vessel diameter was greater in lesions with ≥400 lm
malapposed distance. The stent-to-reference vessel diameter
ratio was smaller in these lesions. Using multivariable
analysis, the stent-to-reference vessel diameter ratio was an
independent predictor for lesions with ≥400 lm malapposed
distance (OR, 0.599 per 0.1 increase; 95% CI, 0.444–0.808
[P=0.0008]). On postintervention OCT, lesions with ≥400 lm
malapposed distance had greater stent and lumen volume
indices, higher malapposed strut percentages, and longer
Table 3. Baseline Characteristics According to ASM Distance
Distance of ASM
P Value≥400 lm
<400 lm or
None
Patients, No. 62 374
Age, y 60.79.4 61.98.9 0.35
Male 49 (79.0) 270 (72.2) 0.26
Diabetes mellitus 20 (32.3) 129 (34.5) 0.73
Hypertension 36 (58.1) 236 (63.1) 0.45
Current smoking 24 (38.7) 95 (25.4) 0.03
Hypercholesterolemia 40 (64.5) 247 (66.0) 0.81
Clinical presentation 0.29
Stable angina 45 (72.6) 257 (68.7)
Unstable angina 10 (16.1) 89 (23.8)
Acute myocardial
infarction
7 (11.3) 28 (7.5)
Previous percutaneous
coronary intervention
5 (8.1) 41 (11.0) 0.49
Previous myocardial
infarction
2 (3.2) 23 (6.2) 0.56
Lesions, No. 63 381
Treated artery 0.11
Left anterior
descending
40 (63.5) 206 (54.1)
Left circumflex 7 (11.1) 87 (22.8)
Right 16 (25.4) 88 (23.1)
Types of implanted
stents
0.30
Sirolimus-eluting
stent
22 (34.9) 99 (26.0)
Biolimus-eluting stent 9 (14.3) 82 (21.5)
Everolimus-eluting
stent
23 (36.5) 129 (33.9)
Zotarolimus-eluting
stent
9 (14.3) 71 (18.6)
No. of implanted stents 1.00.2 1.00.2 0.80
Stent diameter, mm 3.30.4 3.20.4 0.011
Stent-to-reference
vessel diameter ratio
1.00.1 1.10.1 <0.001
Total stent length, mm 19.25.8 18.84.9 0.60
Adjuvant balloon 41 (65.1) 209 (54.9) 0.13
Inflation pressure, atm 16.93.9 16.53.9 0.62
Preintervention angiography
Reference vessel
diameter, mm
3.30.5 3.00.5 <0.001
Minimal lumen
diameter, mm
1.00.5 1.00.5 0.64
Continued
Table 3. Continued
Distance of ASM
P Value≥400 lm
<400 lm or
None
Lesion length, mm 16.86.1 16.25.1 0.48
Postintervention angiography
Reference vessel
diameter, mm
3.40.5 3.10.4 <0.001
Minimal lumen
diameter, mm
3.10.5 2.80.4 <0.001
Postintervention optical coherence tomography
Stent volume index,
mm3/mm
8.3 (6.9–10.7) 7.3 (6.0–8.6) 0.008
Lumen volume index,
mm3/mm
8.0 (6.6–10.4) 7.1 (5.8–8.4) 0.008
Malapposed struts, % 7.1 (4.1–11.6) 1.0 (0–3.1) <0.001
Maximal strut-to-wall
distance, lm
492 (450–607) 161 (120–240) <0.001
Maximal malapposed
length, mm
1.8 (1.0–3.4) 0.2 (0–1.6) 0.003
Results are presented as number (percentage), meanSD, or median (interquartile
range). ASM indicates acute stent malapposition.
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malapposed lengths, compared with those with no ASM or
<400 lm of maximal ASM distance. These ﬁndings persisted
on follow-up OCTs (Table 4). During 5 years of follow-up,
cardiac death occurred in 1 patient and noncardiac death in 5
patients. Thus, among the eligible 430 patients, 370 (86.0%)
completed the 5-year follow-up and the other 60 (14.0%) were
censored during the follow-up. Table 5 presents 5-year
clinical outcomes according to malapposed distance. There
was no difference in the 5-year composite outcome of cardiac
death, target lesion–related myocardial infarction, target
lesion revascularization, and deﬁnite/probable stent throm-
bosis, between the 2 groups (Figure 3A) and among the 3
groups with ASM ≥400 lm, ASM <400 lm, and those
without ASM (Figure 4A).
ASM Length
Of 444 lesions, 188 (42.3%) lesions showed ≥1 mm of
maximum ASM length (Figure 2). The results for baseline
characteristics according to malapposed length are presented
in Table 6. Angiography revealed that reference vessel
diameter was greater and lesion length was longer in lesions
with ≥1 mm malapposed length. The stent-to-reference vessel
diameter ratio was smaller and the total stent length was
longer in lesions with ≥1 mm malapposed length. Using
multivariable analysis, the stent-to-reference vessel diameter
ratio (OR, 0.740 per 0.1 increase; 95% CI, 0.608–0.901
[P=0.0028]), total stent length (OR, 1.048 per 1 mm increase;
95% CI, 1.004–1.094 [P=0.0316]), and the usage of adjuvant
balloon (OR, 0.539; 95% CI, 0.340–0.855 [P=0.0088]) were
independent predictors for lesions with ≥1 mm malapposed
length. Postintervention OCT revealed that lesions with
≥1 mm malapposed length had greater stent and lumen
volume indices, higher percentages of malapposed struts, and
greater strut-to-wall distances, compared with those with no
ASM or <1 mm of malapposed length. These characteristics
were also present on follow-up OCT (Table 7). Table 8
presents the results for 5-year clinical outcomes, according
to malapposed length. There was no distinct between-group
difference in 5-year composite outcome (Figure 3B). The risk
of composite outcome was not increased in patients with
ASM compared with those without ASM (Figure 4B).
Figure 5 represents Kaplan–Meier event curves for the
composite outcome between patients with versus those
without severe ASM. There was no difference between the 2
groups in the 5-year composite outcome (hazard ratio, 0.636;
95% CI, 0.166–3.472 [P=0.66]).
Discussion
In this OCT study, severe ASM characterized by maximal axial
distance or consecutive length was not uncommon, even in
noncomplex lesions treated using DESs. The stent-to-reference
Table 4. Follow-Up OCT Findings According to ASM Distance
Distance of ASM
P Value≥400 lm (n=54)
<400 lm or
None (n=341)
Time intervals after
stenting, mo
4.51.6 4.62.0 0.53
Stent volume index,
mm3/mm
8.4 (7.0–10.6) 7.4 (6.0–8.7) 0.009
Lumen volume index,
mm3/mm
8.0 (6.5–9.8) 6.9 (5.6–8.2) 0.007
Neointimal volume
index, mm3/mm
0.4 (0.3–0.5) 0.4 (0.2–0.6) 0.95
Malapposed struts, % 0.9 (0–3.2) 0 (0–0.7) 0.011
Maximal strut-to-wall
distance, lm
221 (146–385) 120 (100–190) 0.004
Maximal malapposed
length, mm
0.2 (0–1.2) 0 (0–0.2) 0.033
Results are presented as number (percentage), meanSD, or median (interquartile
range). ASM indicates acute stent malapposition; OCT, optical coherence tomography.
Table 5. Five-Year Clinical Outcomes According to ASM
Distance
Distance of ASM
HR (95% CI) P Value
≥400 lm
(n=62)
<400 lm
or None
(n=374)
Cardiac death* 1 (1.7) 0  0.14
Any MI* 0 8 (2.2)  0.61
Target lesion–
related MI*
0 2 (0.6)  1.00
TLR* 1 (1.7) 11 (3.1)  1.00
Definite/probable
ST*
0 1 (0.3)  1.00
Composite of
cardiac death,
target lesion–
related MI,
and definite/
probable ST*
1 (1.7) 2 (0.6)  0.37
Composite of
cardiac death,
target lesion–
related MI,
definite/
probable ST
and TLR
2 (3.3) 11 (3.1) 1.108
(0.245–5.017)
0.89
Results are presented as number (percentage). ASM indicates acute stent malapposition;
HR, hazard ratio; MI, myocardial infarction; OCT, optical coherence tomography; ST, stent
thrombosis; TLR, target lesion revascularization.
*Fisher exact test was used because there were few events.
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vessel diameter ratio was consistently smaller in lesions
with severe ASM, compared with those without severe
ASM. The follow-up OCTs revealed that maximal strut-to-
wall distance of late stent malapposition was greater in
patients with severe ASM compared with those without
severe ASM. However, severe ASM was not associated with
adverse clinical events during the post-DES implantation
5-year follow-up.
This is the ﬁrst OCT-based analysis to investigate the
effects of severe ASM after DES implantation. ASM was found
Figure 4. Kaplan–Meier event curves for composite outcome among 3 groups according to the distance and length of acute stent
malapposition (ASM). (A) Maximal ASM distance, (B) maximal ASM length. Line indicates the patients with severe ASM; dashed dotted line
indicates the patients with nonsevere ASM; dotted line indicates the patients without ASM. HR indicates hazard ratio.
Figure 3. Kaplan–Meier event curves for the composite outcome of cardiac death, target lesion–related myocardial infarction, target lesion
revascularization, and stent thrombosis between 2 groups according to the distance and length of acute stent malapposition (ASM). (A) Maximal
ASM distance, (B) maximal ASM length. Line indicates the patients with severe ASM; dotted line indicates the patients without severe ASM. HR
indicates hazard ratio.
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in 73.4% (326/444) of noncomplex lesions. Severe ASM
(≥400 lm of maximum malapposed distance or ≥1 mm of
maximum malapposed length) was found in 44.8% (199/444)
of the lesions. The ASM incidence was comparable to
previous OCT study ﬁndings18–20; the incidence of severe
ASM was higher than expected. The ASM length component
accounted for 94.5% of the severe ASM (188/199 lesions)
cases. The 82.5% of the 63 lesions with ≥400 lm of
maximum ASM distance also had ≥1 mm of maximum
malapposed length. In contrast, the 72.3% of the 188 lesions
with ≥1 mm of maximum ASM length did not have ≥400 lm
of maximum malapposed distance. The factor of ≥1 mm
maximum ASM length reﬂects a wider range of ASM
compared with the ASM distance.
The stent-to-reference vessel diameter ratio was an
important factor for lesions with ≥400 lm maximum ASM
distance and those with ≥1 mm maximum ASM length. The
mean ratio for lesions with severe ASM was 1.0, and was 1.1
for lesions without severe ASM. There are 2 possible causes
of ASM development: (1) marked mismatch between stent
size selection and luminal dimensions, or (2) stent underex-
pansion caused by factors such as inadequate implantation
pressure or plaque-related factors (calciﬁcations), or both,
despite an adequate stent-artery ratio.21 The adjuvant balloon
was used for more than one half of all lesions and complex
coronary lesions were excluded from the analysis. Therefore,
these ﬁndings suggested that a stent that is 10% larger than
Table 6. Baseline Characteristics According to the Length of
ASM
Length of ASM
P Value≥1 mm <1 mm or None
Patients, No. 186 250
Age, y 62.88.9 60.98.9 0.026
Men 128 (68.8) 191 (76.4) 0.08
Diabetes mellitus 64 (34.4) 85 (34.0) 0.93
Hypertension 115 (61.8) 157 (62.8) 0.84
Current smoking 54 (29.0) 65 (26.0) 0.48
Hypercholesterolemia 130 (69.9) 157 (62.8) 0.12
Clinical presentation 0.19
Stable angina 137 (73.7) 165 (66.0)
Unstable angina 34 (18.3) 65 (26.0)
Acute myocardial
infarction
15 (8.1) 20 (8.0)
Previous percutaneous
coronary intervention
21 (11.3) 25 (10.0) 0.66
Previous myocardial
infarction
14 (7.5) 11 (4.4) 0.16
Lesions, No. 188 256
Treated artery 0.13
Left anterior
descending
102 (54.3) 144 (56.3)
Left circumflex 34 (18.1) 60 (23.4)
Right 52 (27.6) 52 (20.3)
Types of implanted
stents
<0.001
Sirolimus-eluting
stent
67 (35.6) 54 (21.1)
Biolimus-eluting stent 47 (25.0) 44 (17.2)
Everolimus-eluting
stent
48 (25.5) 104 (40.6)
Zotarolimus-eluting
stent
26 (13.8) 54 (21.1)
No. of implanted stents 1.00.2 1.00.2 0.60
Stent diameter, mm 3.20.3 3.20.4 0.85
Stent-to-reference
vessel diameter ratio
1.00.1 1.10.1 <0.001
Total stent length, mm 19.65.5 18.44.6 0.021
Adjuvant balloon 118 (62.8) 132 (51.6) 0.019
Inflation pressure, atm 16.84.0 16.43.8 0.39
Preintervention angiography
Reference vessel
diameter, mm
3.20.5 3.00.4 0.003
Minimal lumen
diameter, mm
1.00.5 1.00.5 0.42
Continued
Table 6. Continued
Length of ASM
P Value≥1 mm <1 mm or None
Lesion length, mm 17.25.8 15.64.7 0.003
Postintervention angiography
Reference vessel
diameter, mm
3.30.5 2.10.4 0.002
Minimal lumen
diameter, mm
2.90.4 2.80.4 0.035
Postintervention optical coherence tomography
Stent volume index,
mm3/mm
7.8 (6.3–9.1) 7.3 (5.9–8.4) 0.046
Lumen volume index,
mm3/mm
7.6 (6.2–8.9) 7.0 (5.7–8.3) 0.033
Malapposed struts, % 4.9 (2.8–8.4) 0.1 (0–1.2) <0.001
Maximal strut-to-wall
distance, lm
286 (194–416) 149 (100–190) <0.001
Maximal malapposed
length, mm
2.0 (1.3–3.6) 0.2 (0–0.2) <0.001
Results are presented as number (percentage), meanSD, or median (interquartile
range). ASM indicates acute stent malapposition; OCT, optical coherence tomography.
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the reference vessel diameter is appropriate for reducing the
risk of severe ASM. Postintervention severe ASM was
correlated with severe malapposed status at follow-up. After
stent implantation, physiologic vascular healing results in
progressive ASM reduction over time.21 However, this
response depends on the degree of ASM. The more severe
the stent malapposition, the greater the possibility of
persistence at follow-up.7–9
The importance of stent size selection was also raised by
the study from Kitahara et al, in which >10% of stent
oversizing to angiographic reference vessel diameter was
associated with a signiﬁcant reduction in the incidence of
stent thrombosis compared with low oversizing in small-sized
vessel (<2.75 mm) but not in large-sized vessel
(≥2.75 mm).22 Given the present results that ASM was not
associated with adverse cardiac events despite the close
relation with stent sizing, it is an interesting ﬁnding that the
relationship between stent size selection and stent thrombo-
sis depended on reference vessel diameter, suggesting the
presence of other links such as footprint.23 Although the
larger-sized vessel in lesions with severe ASM might mask the
potential risk of stent thrombosis in the present study, the
incidence of stent thrombosis in large-sized vessel was not
signiﬁcantly different between oversized stents versus others
from the study by Kitahara et al.22
Previous intravascular ultrasound or OCT studies have
consistently found negative associations between ASM and
clinical events.1,2,24,25 This study provides more information
about ASM severity and clinical outcomes, including results
from up to 5 years after DES implantation. Nevertheless,
stent malapposition has been identiﬁed in patients with stent
thrombosis and may be one of the important mechanisms
causing stent thrombosis.3–5 Pathology studies of stent
thrombosis may help understand the discordance among
OCT study results. An autopsy study by Nakazawa et al26
Table 7. Follow-Up OCT Findings According to the Length of
ASM
Length of ASM
P Value≥1 mm (n=173)
<1 mm or
None (n=222)
Time intervals after
stenting, mo
4.81.7 4.52.2 0.06
Stent volume index,
mm3/mm
7.7 (6.4–9.1) 7.3 (5.9–8.7) 0.045
Lumen volume index,
mm3/mm
7.2 (6.0–8.6) 6.8 (5.5–8.1) 0.016
Neointimal volume index,
mm3/mm
0.3 (0.2–0.5) 0.4 (0.3–0.8) 0.012
Malapposed struts, % 0.4 (0–2.8) 0 (0–0.3) 0.001
Maximal distance of
strut-to-vessel wall, lm
150 (120–300) 110 (90–157) 0.004
Maximal length of
malapposed struts, mm
0.2 (0–1.0) 0 (0–0.2) 0.002
Results are presented as meanSD or median (interquartile range). ASM indicates acute
stent malapposition; OCT, optical coherence tomography.
Table 8. Five-Year Clinical Outcomes According to the
Length of ASM
Length of ASM
HR (95% CI) P Value
≥1 mm
(n=186)
<1 mm
or None
(n=250)
Cardiac death* 0 1 (0.4)  1.00
Any MI* 2 (1.2) 6 (2.5)  0.48
Target lesion–
related MI*
1 (0.6) 1 (0.4)  1.00
TLR* 2 (1.2) 10 (4.2)  0.08
Definite/probable
ST*
1 (0.6) 0  0.43
Composite of cardiac
death, target lesion
–related MI, and
definite/probable
ST*
1 (0.6) 2 (0.8)  1.00
Composite of cardiac
death, target lesion
–related MI,
definite/probable
ST and TLR
2 (1.2) 11 (4.6) 0.240
(0.053–1.089)
0.06
Results are presented as number (percentage). ASM indicates acute stent malapposition;
HR indicates hazard ratio; MI, myocardial infarction; ST, stent thrombosis; TLR, target
lesion revascularization.
*Fisher exact test was used because there were few events.
Figure 5. Kaplan–Meier event curves for composite outcome
between patients with (line) vs those without severe acute stent
malapposition (dotted line).
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found that localized strut hypersensitivity was exclusive to
late thrombosis associated with sirolimus-eluting stent use,
and suggested that the chronic inﬂammation was related to
increased thrombogenicity. Vascular healing was stimulated
by the stenting injury of the vessel wall.27 Therefore,
compared with apposed struts, severe ASM will not initiate
the wound healing inﬂammatory cascade because the stent
ﬂoats in the lumen without touching the vessel wall. The
persistent hypersensitivity reactions that are possibly related
to the use of polymers or antiproliferative drugs may be
attenuated in malapposed struts. The severe ASM found with
currently available limus-based DES might alone be insufﬁ-
cient to trigger stent thrombosis. However, late-acquired
stent malapposition might be associated with a mechanism
different from ASM. With increasing thrombogenicity, chronic
inﬂammation is associated with local release of collagenases
that weaken and lead to the expansion of the vessel wall
(positive arterial remodeling).28 Steady changes that result in
a local environment where thrombi are easily developed may
explain the phenomenon in which stent malapposition is
found in patients with late or very late stent thrombosis.
Associations between late-acquired stent malapposition and
adverse cardiac events remain to be determined.29,30
Study Limitations
This study has some limitations. First, differences between
the protocols used for the randomized studies might have
introduced bias. Second, given the low incidence of adverse
clinical events, the statistical power of this study might have
been too low to detect between-group differences in clinical
outcomes. Thus, there was a potential risk of type II error.
Third, the results should not be generalized to populations of
patients with complex coronary lesions. These limitations
warrant further studies to conﬁrm the clinical impact of
severe ASM.
Conclusions
Severe ASM was not uncommon, even in noncomplex
coronary lesions treated with DES. However, severe ASM
was not associated with poor long-term clinical outcomes in
these patients.
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